multiple dose studies [Design Issues]

posted by Loky do – Egypt, 2024-03-11 12:20 (97 d 16:49 ago) – Posting: # 23900
Views: 1,014

❝ As this is FDC- both the drug needs to be analyzed and thus also consider Solifenacin for washout consideration.

I'm a little confused :confused: why to analyze solifenacin as it is immediate release and the concern towards tamsulosin as it is the delayed release one, even if I took into consideration the washout of both, are the results of solifenacin, in this case, affect those of tamsulosin?

Regards,
Loky


Edit: Full quote removed. Please delete everything from the text of the original poster which is not necessary in understanding your answer; see also this post #5[Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
23,057 posts in 4,840 threads, 1,641 registered users;
155 visitors (0 registered, 155 guests [including 75 identified bots]).
Forum time: 06:09 CEST (Europe/Vienna)

If you tell the truth you don’t have to remember anything.    Mark Twain

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5